A couple of thoughts as the work progresses, unclear how the issue of patients who don't have access to the internet or non users would be supported to participate-or should this be more clearly specified as exclusion criteria.
It is slightly unclear, and this may be the limits of the scope of the current paper, how when the number of APP in FCP is small the service will be able to switch between "normal care" APP minus prescribing to intervention normal care plus IP. Is the assumption that by the time the work progresses to full trial that any service included in the study would have more than one APP FCP? It is a bit unclear if the switch would involve the same person (just not using the prescribing qualification) or a 2nd APP FCP 
REVIEWER

Fan Li Duke Univeristy School of Medicine
REVIEW RETURNED
18-Feb-2019
GENERAL COMMENTS
The protocol is very well written, and I look forward to seeing the results of the feasibility trial. My only comment is that, even though there are concerns in estimating intraclass correlation coefficient (ICC) using the feasibility data, such attempts should be warranted and documented in the protocol. One could use the ANOVA estimator to estimate ICC, and the resulting estimates should be more informative than random guesses. If no attempts are made for the ICC estimation, it is generally difficult to find ICC values in prior literature since these designs are just becoming popular.
VERSION 1 -AUTHOR RESPONSE
Reviewer 1 An interesting and well written paper that thoroughly addresses each stage of the proposed feasibility study.
Thank you for your comments.
We agree that this is an issue that in a full trial we would work around via provision of paper copies of the questionnaire being provided, and ability to send completed questionnaires back in the post via stamped addressed envelopes provided. The feasibility trial aimed to evaluate the feasibility and acceptability of the online version of the questionnaire for patients and the feasibility of data collection using this method in a full trial. To clarify we have added the following wording to the exclusion criteria:
 Unable to receive email and/or complete online questionnaires
It is slightly unclear, and this may be the limits of the scope of the current paper, how when the number of APP in FCP is small the service will be able to switch between "normal care" APP minus prescribing to intervention normal care plus IP. Is the assumption that by the time the work progresses to full trial that any service included in the study would have more than one APP FCP? It is a bit unclear if the switch would involve the same person (just not using the prescribing qualification) or a 2nd APP FCP Thank you for your comments and questions. It is the assumption that as FCP numbers grow (as per NHS England mandate) and services will have more than x1 FCP. It will take time for these clinicians to qualify as independent prescribers. Clinicians who are not prescribers will start in the control group but would switch to the experimental group following qualification. To clarify this point for the reader the following text has been added:
'As the implementation of independent physiotherapy prescribing and the utilisation of APPs working as FCPs are both relatively contemporary innovations, there are limited numbers of clinicians currently working in these innovative roles who are registered to prescribe. This research design allows for the use of fewer clinicians than those required for a parallel design and is therefore more reflective of current practice. APPs who are not prescribers will start in the control group and cross to the experimental group following registration as an independent prescriber.(38-41)'
Reviewer 2 *Page 9, lines 41-46. Currently, controlled drug restrictions mean that Physio IP's cannot prescribe a number of medicines used in the management of Current and pending restrictions to physiotherapist independent prescribing will, as identified by the reviewer, effect the ability of FCPs to prescribe in line with current NICE guidelines for LBP and associated LBP including codeine preparations, tramadol, and (from April 2019) gabapentin and pregabalin. CD restrictions have been highlighted as a significant barrier to NMP practice in the past. Can authors clarify how this scenario will impact data collection in the experimental arm.
leg pain. This scenario will not impact this feasibility trial and the issue will be resolved prior to completion of a full trial. We are in close communication with both the Chartered Society of Physiotherapy (CSP) and Health Education England with regards to the points raised. It is predicted by the professional advisors at the CSP, following Brexit, the highlighted issues will be dealt with by government. Time is also required for the embedding of FCP services across CCGs in England following the current national pilot over the next year. It is therefore expected that the full trial will commence following this time period.
*An Evaluation of physiotherapy, podiatrist independent prescribing, mixing of medicine and prescribing of controlled drugs funded by the dept of Health was published by Carey et al. in 2017.
Authors may wish to demonstrate consideration of this work in the background section.
The following wording has been added to enhance the readers knowledge re the evaluation completed.
'Independent physiotherapist prescribing remains relatively new, with the first prescribers qualifying in 2014. Evaluation of physiotherapist and podiatrist independent prescribing has shown good acceptance by patients and a good safety record to date. Thank you for this comment. This is correct and the typographical error has been corrected.
Reviewer 3
I was asked by the Editor to perform only the Statistical review The authors are clear about their study design which is a single arm feasibility study. They justify why sample calculation was not necessary. Both quantitative and qualitative data analysis are adequate.
Reviewer 4
The protocol is very well written, and I look forward to seeing the results of the feasibility trial. My only comment is that, even though there are concerns in estimating intraclass correlation coefficient (ICC) using the feasibility data, such attempts should be warranted and documented in the protocol. One could use the ANOVA estimator to estimate ICC, and the resulting estimates should be more informative than random Thank you for your comment. We decided not to estimate ICC based on the current literature which expresses concern re feasibility data. Our reasoning for our analysis is stated in the manuscript and the literature is referenced. As the feasibility trial objectives do not aim to assess how strongly the data within the control arm resemble each other, estimation of ICC was not thought necessary at feasibility level. 
